Group sequential testing for cluster randomized trials with time-to-event endpoint

被引:0
|
作者
Li, Jianghao [1 ]
Jung, Sin-Ho [1 ]
机构
[1] Duke Univ, Dept Biostat & Bioinformat, Sch Med, Durham, NC 27705 USA
关键词
alpha spending function; dependent increment; expected sample size; intracluster correlation coefficient; log-rank test; variable cluster size; MAXIMUM DURATION; LOGRANK TESTS; DESIGN;
D O I
10.1111/biom.13498
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We propose group sequential methods for cluster randomized trials (CRTs) with time-to-event endpoint. The alpha spending function approach is used for sequential data monitoring. The key to this approach is determining the joint distribution of test statistics and the information fraction at the time of interim analysis. We prove that the sequentially computed log-rank statistics in CRTs do not have independent increment property. We also propose an information fraction for group sequential trials with clustered survival data and a corresponding sample size determination approach. Extensive simulation studies are conducted to evaluate the performance of our proposed testing procedure using some existing alpha spending functions in terms of expected sample size and maximal sample size. Real study examples are taken to demonstrate our method.
引用
收藏
页码:1353 / 1364
页数:12
相关论文
共 50 条
  • [1] Sample size calculation for cluster randomization trials with a time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    [J]. STATISTICS IN MEDICINE, 2020, 39 (25) : 3608 - 3623
  • [2] Consideration of stratification in confirmatory trials with time-to-event endpoint
    Wang, Yizhuo
    Zhou, Xuan
    Guo, Zifang
    Fang, Xiao
    Liu, Fang
    Shen, Liji
    [J]. CONTEMPORARY CLINICAL TRIALS, 2024, 141
  • [3] On the estimation of intracluster correlation for time-to-event outcomes in cluster randomized trials
    Kalia, Sumeet
    Klar, Neil
    Donner, Allan
    [J]. STATISTICS IN MEDICINE, 2016, 35 (30) : 5551 - 5560
  • [4] Guidelines for time-to-event endpoint definitions in randomized cancer trials for sarcomas and GIST: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Bellera, C.
    Ouali, M.
    Penel, N.
    Litiere, S.
    Casali, P.
    Bonvalot, S.
    Nielsen, O. S.
    Delannes, M.
    Mathoulin-Pelissier, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S881 - S881
  • [5] Milestone prediction for time-to-event endpoint monitoring in clinical trials
    Ou, Fang-Shu
    Heller, Martin
    Shi, Qian
    [J]. PHARMACEUTICAL STATISTICS, 2019, 18 (04) : 433 - 446
  • [6] A Bayesian adaptive design for biosimilar trials with time-to-event endpoint
    Belay, Sheferaw Y.
    Mu, Rongji
    Xu, Jin
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (03) : 597 - 609
  • [7] Predicting study duration in clinical trials with a time-to-event endpoint
    Machida, Ryunosuke
    Fujii, Yosuke
    Sozu, Takashi
    [J]. STATISTICS IN MEDICINE, 2021, 40 (10) : 2413 - 2421
  • [8] Sample size in cluster-randomized trials with time to event as the primary endpoint
    Jahn-Eimermacher, Antje
    Ingel, Katharina
    Schneider, Astrid
    [J]. STATISTICS IN MEDICINE, 2013, 32 (05) : 739 - 751
  • [9] Sample size calculation for randomized selection trials with a time-to-event endpoint and a margin of practical equivalence
    Dehbi, Hakim-Moulay
    Embleton-Thirsk, Andrew
    McCaw, Zachary Ryan
    [J]. STATISTICS IN MEDICINE, 2022, 41 (20) : 4022 - 4033
  • [10] Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings
    Emerson, Sarah C.
    Rudser, Kyle D.
    Emerson, Scott S.
    [J]. STATISTICS IN MEDICINE, 2011, 30 (11) : 1199 - 1217